India to Taiwan: Cisplatin Export Trade Route

The India to Taiwan Cisplatin corridor is one of India's established pharmaceutical export routes, with 20 shipments documented worth a combined $1.6M USD. The route is dominated by FRESENIUS KABI ONCOLOGY LIMITED, which alone accounts for roughly 80% of all export value, reflecting the consolidated nature of India's cisplatin manufacturing sector.

Across 2 active suppliers, the average shipment value stands at $79.6K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Freight is split between sea (67%) and air (16%), suggesting a mix of scheduled bulk orders and time-sensitive consignments.

Shipment activity peaks during July–September, with an average transit time of 26 days port-to-port. The route has recorded an annual growth rate of 26.8%, placing it at rank #14 among India's top cisplatin export destinations globally.

On the import side, key buyers of Indian cisplatin in Taiwan include FRESENIUS KABI TAIWAN LTD., FRESENIUS KABI TAIWAN LTD, FRESENIUS KABI TAIWAN LTD., and 4 others. FRESENIUS KABI TAIWAN LTD. is the single largest importer with 6 shipments valued at $439.1K USD.

India's cisplatin exports to Taiwan are driven primarily by a handful of large-scale manufacturers. FRESENIUS KABI ONCOLOGY LIMITED with 16 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 2 active exporters signals a competitive but concentrated market — buyers in Taiwan benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — FRESENIUS KABI ONCOLOGY LIMITED, FRESENIUS KABI ONCOLOGY LIMITED — together account for 100% of total trade value on this route. The average shipment value of $79.6K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as kemoplat (cisplatin) bp inj. 50mg/50ml v and kemoplat cisplatin bp inj 50mg 50mlvial batch no 87230067ab 87230067ad mfg dt 02 2023 exp dt 01 2025, suggesting that buyers in Taiwan tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, FRESENIUS KABI TAIWAN LTD. is the largest importer with 6 shipments worth $439.1K USD — representing 28% of all cisplatin imports from India on this route. A total of 7 buyers are active on this corridor.